Impact of CYP2D6 genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 International Diabetes Foundation. www.idf.org.
  Google Scholar
• 2 Boulton AJM. Management of diabetic peripheral neuropathy. Clin. Diabetes 23, 9–15 (2005).
  Google Scholar
• 3 Boulton AJ, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet. Med. 15, 508–514 (1998).
  Medline CASGoogle Scholar
• 4 Ulugol A, Karadag HC, Tamer M, Firat Z, Aslantas A, Dokmeci I. Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocin-induced diabetic rats. Neurosci. Lett. 328, 129–132 (2002).
  Medline CASGoogle Scholar
• 5 Devi P, Madhu K, Ganapathy B, Sarma G, John L, Kulkarni C. Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy. Indian J. Pharmacol. 44, 51–56 (2012).
  MedlineGoogle Scholar
• 6 Gore M, Brandenburg NA, Hoffman DL, Tai K-S, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: the patients’ perspectives. J. Pain 7, 892–900 (2006).
  MedlineGoogle Scholar
• 7 Attal N, Cruccu G, Haanpää M et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur. J. Neurol. 13, 1153–1169 (2006).
  Medline CASGoogle Scholar
• 8 Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 11, 521–534 (2012).
  MedlineGoogle Scholar
• 9 Steimer W, Zöpf K, Von Amelunxen S et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin. Chem. 51, 376–385 (2005).
  Medline CASGoogle Scholar
• 10 Chetty S, Baalbergen E, Bhigjee AI et al. Clinical practice guidelines for management of neuropathic pain: expert panel recommendations for South Africa. SAMJ. 102, 312–325 (2012).
  Medline CASGoogle Scholar
• 11 The Human Cytochrome P450 (CYP) Allele Nomenclature Database. www.cypalleles.ki.se/.
  Google Scholar
• 12 Teh LK, Bertilsson L. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab. Pharmacokinet. 27, 55–67 (2012).
  Medline CASGoogle Scholar
• 13 Zhou S-F, Liu J-P, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev. 41, 89–295 (2009).
  Medline CASGoogle Scholar
• 14 Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet. Med. 19, 69–76 (2017). •• This is the first comprehensive study that summarizes allele frequencies, diplotypes and predicted phenotype across major populations, providing a rich data resource for clinicians and researchers.
  MedlineGoogle Scholar
• 15 Llerena A, Dorado P, Peñas-Lledó EM. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. 10(1), 17–28 (2009).
  Google Scholar
• 16 Llerena A, Naranjo MEG, Rodrigues-Soares F, Penas-Lledó EM, Fariñas H, Tarazona-Santos E. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin. Drug Metab. Toxicol. 10(11), 1569–1583 (2014).
  Medline CASGoogle Scholar
• 17 Caudle KE, Dunnenberger HM, Freimuth RR et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet. Med. 19(2), 215–223 (2017). •• It is of considerable interest because it provides standardized pharmacogenetic terms that will facilitate reporting and sharing of pharmacogenetic tests.
  MedlineGoogle Scholar
• 18 Hicks JK, Swen JJ, Thorn CF et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther. 93, 402–408 (2013). •• It is of considerable interest because it provides dose recommendations for tricyclic antidepressants.
  Medline CASGoogle Scholar
• 19 Hicks JK, Sangkuhl K, Swen JJ et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC^®) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin. Pharmacol. Ther. doi:10.1002/cpt.597 (2016) (Epub ahead of print).
  MedlineGoogle Scholar
• 20 Jiang Z-P, Shu Y, Chen X-P et al. The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. Eur. J. Clin. Pharmacol. 58, 109–113 (2002).
  Medline CASGoogle Scholar
• 21 Mayfield JA, Sugarman JR. The use of the Semmes–Weinstein monofilament and other threshold tests for preventing foot ulceration and amputation in persons with diabetes. J. Fam. Pract. 49(11), S17–S17 (2000).
  Medline CASGoogle Scholar
• 22 Dodgen TM, Hochfeld WE, Fickl H et al. Introduction of the AmpliChip CYP450 test to a South African cohort: a platform comparative prospective cohort study. BMC Med. Genet. 14, 20 (2013). • Provides useful information on genetic diversity of South African population in context to CYP2D6.
  Medline CASGoogle Scholar
• 23 The Human Cytochrome P450 (CYP) Allele Nomenclature Database. www.cypalleles.ki.se/cyp2d6.htm.
  Google Scholar
• 24 Twist GP, Gaedigk A, Miller NA et al. Constellation: a tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene, CYP2D6, from whole-genome sequences. NPJ Genom. Med. 1, 15007 (2016).
  Medline CASGoogle Scholar
• 25 Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83, 234–242 (2008). • The key paper on CYP2D6 activity score to determine individual phenotype from genotype.
  Medline CASGoogle Scholar
• 26 Dunn OJ. Estimation of the means of dependent variables. Ann. Math. Stat. 29(4), 1095–1111 (1958).
  Google Scholar
• 27 Weisstein EW. Noncentral F-Distribution (2002). http://mathworld.wolfram.com/NoncentralF-Distribution.html.
  Google Scholar
• 28 Dodgen TM, Labuschagne CDJ, Van Schalkwyk A et al. Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort. Pharmacogenomics J. 16, 566–572 (2015).
  MedlineGoogle Scholar
• 29 Gaedigk A, Coetsee C. The CYP2D6 gene locus in South African coloureds: unique allele distributions, novel alleles and gene arrangements. Eur. J. Clin. Pharmacol. 64(5), 465–475 (2008).
  Medline CASGoogle Scholar
• 30 Wright GE, Niehaus DJ, Drögemöller BI, Koen L, Gaedigk A, Warnich L. Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann. Hum. Genet. 74(4), 340–350 (2010).
  Medline CASGoogle Scholar
• 31 Nakajima M, Inoue T, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab. Dispos. 26(3), 261–266 (1998).
  Medline CASGoogle Scholar
• 32 Xie G, Zhou D, Cheng K-W, Wong CC, Rigas B. Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans. Biochem. Pharmacol. 85(8), 1195–1202 (2013).
  Medline CASGoogle Scholar
• 33 Ziegler D, Fonseca V. From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. J. Diabetes Complications 29(1), 146–156 (2015).
  MedlineGoogle Scholar